Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Rousseau

Showing results (21-30 of 119) with videos related to

Pageof 12
Sort By:
Cancers|September 28, 2024
Are Dual-Phase <sup>18</sup>F-Fluorodeoxyglucose PET-mpMRI Diagnostic Performances to Distinguish Brain Tumour Radionecrosis/Recurrence after Cranial Radiotherapy Usable in Routine?Axel Cailleteau, Ludovic Ferrer, Delphine Geffroy, et al.
Clinical Nuclear Medicine|May 11, 2022
Bone Uptake in Prostate Cancer Patients: Diagnostic Performances of PSMA-RADS v1.0, Clinical, Biological, and 68 Ga-PSMA-11 PET Features to Predict Metastasis After Biochemical RecurrenceAnouk Letang, Amandine Crombé, Caroline Rousseau, et al.
EJNMMI Radiopharmacy and Chemistry|March 6, 2018
Pretargeting for imaging and therapy in oncological nuclear medicineClément Bailly, Caroline Bodet-Milin, Caroline Rousseau, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|August 21, 2025
Temporal footprint reduction via neural network denoising in 177Lu radioligand therapyMax Celio Nzatsi, Nicolas Varmenot, David Sarrut, et al.
Frontiers in Oncology|June 27, 2013
Improvement of radioimmunotherapy using pretargetingEric Frampas, Caroline Rousseau, Caroline Bodet-Milin, et al.
Frontiers in Medicine|October 31, 2022
Immuno-PET: Design options and clinical proof-of-conceptAlexandre Lugat, Clément Bailly, Michel Chérel, et al.
The Journal of Steroid Biochemistry and Molecular Biology|August 29, 2003
The N-terminal of the estrogen receptor (ERalpha) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cellsCaroline Rousseau, Filippa Pettersson, Marie Claude Couture, et al.
Clinical Nuclear Medicine|April 15, 2022
Is Glucagon Administration Compatible With FDG PET/MRI?Bruno Maucherat, Roshanack Movassaghi, Vincent Fleury, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2007
Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrenceChantal Curtet, Thomas Carlier, Eric Mirallié, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 30, 2020
Incidental findings suggestive of COVID-19 in asymptomatic cancer patients undergoing 18F-FDG PET/CT in a low prevalence regionAmandine Pallardy, Caroline Rousseau, Catherine Labbe, et al.
Pageof 12

Showing results (21-30 of 119) with videos related to

Sort By:
Pageof 12
Cancers|September 28, 2024
Are Dual-Phase <sup>18</sup>F-Fluorodeoxyglucose PET-mpMRI Diagnostic Performances to Distinguish Brain Tumour Radionecrosis/Recurrence after Cranial Radiotherapy Usable in Routine?Axel Cailleteau, Ludovic Ferrer, Delphine Geffroy, et al.
Clinical Nuclear Medicine|May 11, 2022
Bone Uptake in Prostate Cancer Patients: Diagnostic Performances of PSMA-RADS v1.0, Clinical, Biological, and 68 Ga-PSMA-11 PET Features to Predict Metastasis After Biochemical RecurrenceAnouk Letang, Amandine Crombé, Caroline Rousseau, et al.
EJNMMI Radiopharmacy and Chemistry|March 6, 2018
Pretargeting for imaging and therapy in oncological nuclear medicineClément Bailly, Caroline Bodet-Milin, Caroline Rousseau, et al.
Physica Medica : PM : an International Journal Devoted to the Applications of Physics to Medicine and Biology : Official Journal of the Italian Association of Biomedical Physics (AIFB)|August 21, 2025
Temporal footprint reduction via neural network denoising in 177Lu radioligand therapyMax Celio Nzatsi, Nicolas Varmenot, David Sarrut, et al.
Frontiers in Oncology|June 27, 2013
Improvement of radioimmunotherapy using pretargetingEric Frampas, Caroline Rousseau, Caroline Bodet-Milin, et al.
Frontiers in Medicine|October 31, 2022
Immuno-PET: Design options and clinical proof-of-conceptAlexandre Lugat, Clément Bailly, Michel Chérel, et al.
The Journal of Steroid Biochemistry and Molecular Biology|August 29, 2003
The N-terminal of the estrogen receptor (ERalpha) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cellsCaroline Rousseau, Filippa Pettersson, Marie Claude Couture, et al.
Clinical Nuclear Medicine|April 15, 2022
Is Glucagon Administration Compatible With FDG PET/MRI?Bruno Maucherat, Roshanack Movassaghi, Vincent Fleury, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2007
Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrenceChantal Curtet, Thomas Carlier, Eric Mirallié, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 30, 2020
Incidental findings suggestive of COVID-19 in asymptomatic cancer patients undergoing 18F-FDG PET/CT in a low prevalence regionAmandine Pallardy, Caroline Rousseau, Catherine Labbe, et al.
Pageof 12